FDA APPROVED DRUGS 2018

Dermatology
Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis ,
Approved March 2018

Family Medicine
Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults ,
Approved May 2018

Gastroenterology
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the
treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Genetic Disease
Crysvita (burosumab-twza) ; Ultragenyx; For the treatment of X-linked hypophosphatemia,
Approved April 2018

Hematology
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola
Pharmaceuticals; for the reversal of factor Xa inhibitors, Approved May 2018
Doptelet (avatrombopag) ; AkaRx; For the treatment of thrombocytopenia in adults with
chronic liver disease scheduled to undergo a procedure, Approved May 2018
Lokelma (sodium zirconium cyclosilicate); AstraZeneca; For the treatment of
hyperkalemia, Approved May 2018
Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment
of chronic immune thrombocytopenia, Approved April 2018

Immunology
Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis ,
Approved March 2018
Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment
of chronic immune thrombocytopenia, Approved April 2018

Infections and Infectious Diseases

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Gilead; For the treatment of
HIV-1 infection in adults, Approved February 2018
Trogarzo (ibalizumab-uiyk); TaiMed Biologics; For the treatment of multidrug resistant
HIV-1 infection, Approved March 2018

www.gpat.pharmacognize.com Contact us: +91-9779737368

Musculoskeletal
Crysvita (burosumab-twza) ; Ultragenyx; For the treatment of X-linked hypophosphatemia,
Approved April 2018

Nephrology
Jynarque (tolvaptan); Otsuka America; For the treatment of autosomal dominant polycystic
kidney disease, Approved April 2018

Neurology
Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults ,
Approved May 2018

Oncology
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved
February 2018
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the
treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Pharmacology/Toxicology
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola
Pharmaceuticals; for the reversal of factor Xa inhibitors, Approved May 2018
Lucemyra (lofexidine); US Worldmeds; For the mitigation of opioid withdrawal symptoms
to facilitate abrupt opioid discontinuation in adults, Approved May 2018

Pulmonary/Respiratory Diseases
Symdeko (tezacaftor/ivacaftor) ; Vertex; For the treatment of cystic fibrosis , Approved
February 2018

Urology
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved
February 2018

www.gpat.pharmacognize.com Contact us: +91-9779737368